Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?

by Aurélien Mary, Aurélien Mary, Lucie Hénaut, Jean-Luc Schmit, Jean-Luc Schmit, Jean-Philippe Lanoix, Jean-Philippe Lanoix, Michel Brazier, Michel Brazier
Published 2020-05-01

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals

by Etienne Brochot, Etienne Brochot, Baptiste Demey, Baptiste Demey, Antoine Touzé, Sandrine Belouzard, Jean Dubuisson, Jean-Luc Schmit, Jean-Luc Schmit, Gilles Duverlie, Gilles Duverlie, Catherine Francois, Catherine Francois, Sandrine Castelain, Sandrine Castelain, Francois Helle
Published 2020-10-01

Number of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients

by Adrien Chan Sui Ko, Alexandre Candellier, Marie Mercier, Cédric Joseph, Jean-Luc Schmit, Jean-Philippe Lanoix, Claire Andrejak
Published 2022-05-01

Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80

by Andreea Rosca, Thibaut Balcaen, Audrey Michaud, Jean-Philippe Lanoix, Julien Moyet, Ingrid Marcq, Jean-Luc Schmit, Frederic Bloch, Guillaume Deschasse
Published 2022-02-01